Switch to
View more

Nectar Lifesciences Ltd

NECLIFE
Health CarePharmaceuticals
SmallcapWith a market cap of ₹549 cr, stock is ranked 1,234
High RiskStock is 3.13x as volatile as Nifty
24.500.30 (+1.24%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Investment Checklist
BasicPro
Go pro! Unlock deeper insights
Health CarePharmaceuticals
SmallcapWith a market cap of ₹549 cr, stock is ranked 1,234
High RiskStock is 3.13x as volatile as Nifty

Key MetricsEdit

PE RatioPE Ratio
21.93
PB RatioPB Ratio
0.52
Dividend YieldDiv. Yield
Sector PESector PE
38.16
Sector PBSector PB
4.82
Sector Div YldSctr Div Yld
0.92%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Nectar Lifesciences Limited is a pharmaceutical company. The Company's operations include manufacturing and marketing of oral and sterile cephalosporin's, phytochemicals and allied products.

Financial TrendFinancial statements 

20192020202120222.792.371.551.680.050.03-0.070.03
Revenue
Profit
Loss
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

High Pledged Promoter Holding
Lower pledged promoter holdings is considered better

A significant proportion of promoter holdings is pledged

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Outcome of Board Meeting 
Announced OnAug 13, 2022

Nectar Lifesciences Limited has informed the Exchange about outcome of Board Meeting held on 13-Aug-2022 to consider financial statements for the period ended June 2022 and appointment of a Director | Download

Nectar Lifesciences Limited has informed the Exchange about outcome of Board Meeting held on 13-Aug-2022 to consider financial statements for the period ended June 2022 and appointment of a Director | Download

Appointment 
Announced OnAug 3, 2022

Nectar Lifesciences Limited has informed the Exchange that the Board of Directors vide their resolution by Circulation passed on August 02, 2022 have appointed Dr. Indu Pal Kaur (DIN 09686862) on the Board as an additional director (independent) of the company till the date of forthcoming Annual General Meeting in which she can be appointed as a regular Independent Director. She is the Woman Director on the Board of the Company. Other relevant disclosures are as per attached letter. | Download

Nectar Lifesciences Limited has informed the Exchange that the Board of Directors vide their resolution by Circulation passed on August 02, 2022 have appointed Dr. Indu Pal Kaur (DIN 09686862) on the Board as an additional director (independent) of the company till the date of forthcoming Annual General Meeting in which she can be appointed as a regular Independent Director. She is the Woman Director on the Board of the Company. Other relevant disclosures are as per attached letter. | Download

Cash Dividend 
Ex. DateSep 11, 2020

Final • Div/Share: ₹ 0.05

See all events